Back to top
more

Nevro (NVRO)

(Real Time Quote from BATS)

$5.07 USD

5.07
61,147

+0.24 (4.97%)

Updated Aug 8, 2024 09:50 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (106 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Nevro (NVRO) Q3 Earnings Top Estimates, FY23 Revenue View Up

by Zacks Equity Research

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in the third quarter, owing to robust domestic performance.

Nevro (NVRO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Nevro (NVRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nevro's (NVRO) New Data Supports SCS Therapy for PDN Treatment

by Zacks Equity Research

Nevro's (NVRO) latest 24-month data demonstrates the benefits of high-frequency 10 kHz SCS implant for durable pain relief and significant improvements in patient condition post-implantation.

Nevro's (NVRO) Latest Launch to Customize Chronic Pain Treatment

by Zacks Equity Research

Nevro's (NVRO) HFX Connect system is expected to treat individual patients per their requirements with 35 pre-programmed customizable plans.

Nevro (NVRO) Q2 Earnings Lag Estimates, FY23 View Cut

by Zacks Equity Research

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in the second quarter owing to robust domestic and international performances.

Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Nevro (NVRO) delivered earnings and revenue surprises of -1.47% and 0.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

MedTech Stocks to Watch for Earnings on Aug 1: ECL, NVRO, INSP

by Debanjana Dey

MedTech companies' Q2 results are likely to reflect strength in customer demand. Let's see how ECL, NVRO and INSP are placed ahead of their earnings releases.

Integer (ITGR) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Integer (ITGR) delivered earnings and revenue surprises of 15.15% and 8.99%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.

Why Is OPKO Health (OPK) Down 17.2% Since Last Earnings Report?

by Zacks Equity Research

OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Nevro (NVRO) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q1, partly owing to robust domestic performance.

Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nevro (NVRO) delivered earnings and revenue surprises of 7.55% and 1.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Ecolab (ECL) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) first-quarter results are likely to reflect continued strength in its Global Industrial segment.

Indrajit Bandyopadhyay headshot

MedTech Stocks' Q1 Earnings Due on Apr 26: MMSI, CNMD & More

by Indrajit Bandyopadhyay

Medical Device players are expected to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how MMSI, CNMD, NVRO and ARAY are likely to have performed this time.

How Much Upside is Left in Nevro (NVRO)? Wall Street Analysts Think 53.7%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 53.7% in Nevro (NVRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Will OrthoPediatrics (KIDS) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

OrthoPediatrics (KIDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nevro's (NVRO) Latest Launch to Customize Chronic Pain Treatment

by Zacks Equity Research

Nevro's (NVRO) Senza HFX iQ SCS system is expected to treat individual patients per their particular treatment requirements.

Nevro (NVRO) Q4 Earnings Lag Estimates, Revenues Beat

by Zacks Equity Research

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q4, partly owing to robust domestic performance.

Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nevro (NVRO) delivered earnings and revenue surprises of -10.20% and 0.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Masimo (MASI) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for West Pharmaceutical (WST) in Q4 Earnings?

by Zacks Equity Research

West Pharmaceutical's (WST) fourth-quarter results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements are likely to hurt the top and the bottom lines.

Will Nevro (NVRO) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in Nevro (NVRO): Can Its 5.1% Jump Turn into More Strength?

by Zacks Equity Research

Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Thermo Fisher Scientific (TMO) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Thermo Fisher (TMO) delivered earnings and revenue surprises of 4.05% and 10.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain Nevro (NVRO) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO), owing to its R&D edge.